Rocket Pharmaceuticals Secures FDA Approval for KRESLADI™, a Landmark Gene Therapy for Severe LAD‑I
Rocket Pharmaceuticals has achieved a major milestone with the FDA’s accelerated approval of KRESLADI™ (marnetegragene autotemcel), the first gene therapy designed to treat children with severe Leukocyte Adhesion Deficiency‑I (LAD‑I). This approval marks a breakthrough for families affected by this ultra‑rare, life‑threatening immune disorder and represents a significant step forward in the field of genetic medicine.
Source:
👉 Official Rocket Pharmaceuticals press release
What Is KRESLADI™?
KRESLADI™ is an autologous hematopoietic stem cell‑based gene therapy, meaning it uses a patient’s own genetically modified stem cells to correct the underlying immune defect caused by mutations in the ITGB2 gene. These mutations prevent white blood cells from functioning properly, leaving children vulnerable to severe, recurrent infections.
The therapy works by restoring expression of CD18 and CD11a, key proteins needed for immune cells to adhere, migrate, and fight infections effectively.
Why This Approval Matters
1. First FDA‑Approved Gene Therapy for Severe LAD‑I
This is the first treatment of its kind for children with severe LAD‑I who do not have a matched sibling donor for stem cell transplantation — previously the only available option, and one associated with significant risks.
2. Accelerated Approval Based on Strong Biomarker Data
The FDA granted accelerated approval based on measurable increases in neutrophil CD18 and CD11a expression, key indicators of restored immune function.
3. Rare Pediatric Disease Priority Review Voucher
With approval, Rocket also received a Rare Pediatric Disease Priority Review Voucher, which the company may monetize to support future development efforts.
What Rocket Pharmaceuticals Says
Rocket’s CEO, Gaurav Shah, M.D., emphasized that this approval reflects years of collaboration among patients, families, clinicians, and regulators. He highlighted the therapy’s potential to transform outcomes for children who previously faced high early‑childhood mortality due to severe LAD‑I.
Understanding Severe LAD‑I
Severe Leukocyte Adhesion Deficiency‑I is an ultra‑rare genetic immunodeficiency caused by biallelic variants in the ITGB2 gene. Children with this condition often experience:
- Recurrent, life‑threatening bacterial and fungal infections
- Poor wound healing
- High mortality in early childhood without treatment
KRESLADI™ offers a new therapeutic path that avoids the complications of donor‑based stem cell transplantation.
Looking Ahead
Rocket Pharmaceuticals plans a measured rollout of KRESLADI™ while continuing long‑term follow‑up studies and maintaining
Disclaimer: Health Evidence Digest provides general information about health research. Content is for informational purposes only and is not a substitute for professional medical advice.